Publications

  1. Leon-Ferre RA, Whitaker KR, Suman VJ, Hoskin T, Giridhar KV, Moore RM, Al-Jarrad A, McLaughlin SA, Northfelt DW, Hunt KN, Conners AL, Moyer A, Carter JM, Kalari K, Weinshilboum R, Wang L, Ingle JN, Knutson KL, Ansell SM, Boughey JC, Goetz MP, Villasboas JC. Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer. Breast Cancer Res. 2024 Jun 10; 26 (1):97 Epub 2024 June 10
    View PubMed
  2. Wickland DP, McNinch C, Jessen E, Necela B, Shreeder B, Lin Y, Knutson KL, Asmann YW. Comprehensive profiling of cancer neoantigens from aberrant RNA splicing. J Immunother Cancer. 2024 May 15; 12 (5)
    View PubMed
  3. Knutson KL. Regulation of Tumor Dendritic Cells by Programmed Cell Death 1 Pathways. J Immunol. 2024 May 1; 212 (9):1397-1405
    View PubMed
  4. Caldera F, Rolak S, Farraye FA, Necela BM, Cogen D, Zona EE, Schell TL, Ramirez OR, Almasry M, Chun K, Hayney MS, Knutson KL. Higher and Sustained Cell-Mediated Immune Responses After 3 Doses of mRNA COVID-19 Vaccine in Patients With Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy. Clin Transl Gastroenterol. 2024 Apr 1; 15 (4):e00688 Epub 2024 Apr 01
    View PubMed
  5. Luo Y, Shreeder B, Jenkins JW, Shi H, Lamichhane P, Zhou K, Bahr DA, Kurian S, Jones KA, Daum JI, Dutta N, Necela BM, Cannon MJ, Block MS, Knutson KL. Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade. J Immunother Cancer. 2023 Nov; 11 (11)
    View PubMed
  6. Carter JM, Chumsri S, Hinerfeld DA, Ma Y, Wang X, Zahrieh D, Hillman DW, Tenner KS, Kachergus JM, Brauer HA, Warren SE, Henderson D, Shi J, Liu Y, Joensuu H, Lindman H, Leon-Ferre RA, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Knutson KL, Goetz MP, Perez EA, Thompson EA. Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer. Nat Commun. 2023 Apr 18; 14(1):2215.
    View PubMed
  7. Ogony J, Hoskin TL, Stallings-Mann M, Winham S, Brahmbhatt R, Arshad MA, Kannan N, Pena A, Allers T, Brown A, Sherman ME, Visscher DW, Knutson KL, Radisky DC, Degnim AC. Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers. Breast Cancer Res Treat. 2023 Jan; 197 (2):277-285 Epub 2022 Nov 16
    View PubMed
  8. An Z, Figueroa-Parra G, Zhou X, Li Y, Jaquith J, McCarthy-Fruin K, Sletten J, Warrington KJ, Weyand C, Crowson CS, Chumsri S, Knutson KL, Sanchez-Rodriguez A, Thanarajasingam U, Duarte-Garcia A, Zeng H. Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients. Front Immunol. 2023; 14:1224702 Epub 2023 July 31
    View PubMed
  9. Yin N, Liu Y, Weems C, Shreeder B, Lou Y, Knutson KL, Murray NR, Fields AP. Protein kinase Ciota mediates immunosuppression in lung adenocarcinoma. Sci Transl Med. 2022 Nov 16; 14 (671):eabq5931
    View PubMed
  10. Schell TL, Knutson KL, Saha S, Wald A, Phan HS, Almasry M, Chun K, Grimes I, Lutz M, Hayney MS, Farraye FA, Caldera F. Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2022 Nov 2; 28 (11):1781-1786
    View PubMed
  11. Vivekanandhan S, Knutson KL. Resistance to Trastuzumab. Cancers (Basel). 2022 Oct 19; 14 (20)
    View PubMed
  12. Sammons S, Raskina K, Danziger N, Alder L, Schrock AB, Venstrom JM, Knutson KL, Thompson EA, McGregor K, Sokol E, Chumsri S. APOBEC Mutational Signatures in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy. JCO Precis Oncol. 2022 Oct; 6:e2200149.
    View PubMed
  13. Vivekanandhan S, Knutson KL. Resistance to trastuzumab. Cancers. 2022 Oct; 14 (20):5115
  14. Yadav H, Meade LA, Carter RE, Knutson K, Gajic O, Kor DJ. Characterization of Platelet Biologic Markers in the Early Pathogenesis of Postoperative Acute Respiratory Distress Syndrome. Crit Care Explor. 2022 Jul; 4 (7):e0728 Epub 2022 July 15
    View PubMed
  15. Chumsri S, Li Z, Serie DJ, Norton N, Mashadi-Hossein A, Tenner K, Brauer HA, Warren S, Danaher P, Colon-Otero G, Partridge AH, Carey LA, Hilbers F, Van Dooren V, Holmes E, Di Cosimo S, Werner O, Huober JB, Dueck AC, Sotiriou C, Saura C, Moreno-Aspitia A, Knutson KL, Perez EA, Thompson EA. Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials. NPJ Breast Cancer. 2022 May 24; 8(1):68.
    View PubMed
  16. Chumsri S, Advani PP, Pai TS, Li Z, Mummareddy A, Acampora M, Reynolds GA, Wylie N, Boyle AW, Lou Y, Mody K, Moreno-Aspitia A, Swift MD, Virk A, Bharucha AE, Marquez CP, Patel TC, Gores GJ, Knutson KL. Humoral Responses After SARS-CoV-2 mRNA Vaccination and Breakthrough Infection in Cancer Patients. Mayo Clin Proc Innov Qual Outcomes. 2022 Apr; 6 (2):120-125 Epub 2021 Dec 13
    View PubMed
  17. Caldera F, Knutson KL, Saha S, Wald A, Phan HS, Chun K, Grimes I, Lutz M, Hayney MS, Farraye FA. Humoral Immunogenicity of mRNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease and Healthy Controls. Am J Gastroenterol. 2022 Jan 1; 117 (1):176-179
    View PubMed
  18. Gabriel EM, Kim M, Fisher DT, Mangum C, Attwood K, Ji W, Mukhopadhyay D, Bagaria SP, Robertson MW, Dinh TA, Knutson KL, Skitzki JJ, Wallace MB. A pilot trial of intravital microscopy in the study of the tumor vasculature of patients with peritoneal carcinomatosis. Sci Rep. 2021 Mar 2; 11 (1):4946 Epub 2021 Mar 02
    View PubMed
  19. Ogony JW, Radisky DC, Ruddy KJ, Goodison S, Wickland DP, Egan KM, Knutson KL, Asmann YW, Sherman ME. Immune Responses and Risk of Triple-negative Breast Cancer: Implications for Higher Rates among African American Women. Cancer Prev Res (Phila). 2020 Nov; 13 (11):901-910 Epub 2020 Aug 04
    View PubMed
  20. Block MS, Dietz AB, Gustafson MP, Kalli KR, Erskine CL, Youssef B, Vijay GV, Allred JB, Pavelko KD, Strausbauch MA, Lin Y, Grudem ME, Jatoi A, Klampe CM, Wahner-Hendrickson AE, Weroha SJ, Glaser GE, Kumar A, Langstraat CL, Solseth ML, Deeds MC, Knutson KL, Cannon MJ. Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. Nat Commun. 2020 Oct 14; 11(1):5173.
    View PubMed
  21. Gabriel EM, Kim M, Fisher DT, Powers C, Attwood K, Bagaria SP, Knutson KL, Skitzki JJ. Dynamic control of tumor vasculature improves antitumor responses in a regional model of melanoma. Sci Rep. 2020 Aug 6; 10 (1):13245 Epub 2020 Aug 06
    View PubMed
  22. Catenacci DVT, Kang YK, Park H, Uronis HE, Lee KW, Ng MCH, Enzinger PC, Park SH, Gold PJ, Lacy J, Hochster HS, Oh SC, Kim YH, Marrone KA, Kelly RJ, Juergens RA, Kim JG, Bendell JC, Alcindor T, Sym SJ, Song EK, Chee CE, Chao Y, Kim S, Lockhart AC, Knutson KL, Yen J, Franovic A, Nordstrom JL, Li D, Wigginton J, Davidson-Moncada JK, Rosales MK, Bang YJ, CP-MGAH22-5 Study Group. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. Lancet Oncol. 2020 Aug; 21 (8):1066-1076 Epub 2020 July 09
    View PubMed
  23. Zamarin D, Walderich S, Holland A, Zhou Q, Iasonos AE, Torrisi JM, Merghoub T, Chesebrough LF, Mcdonnell AS, Gallagher JM, Li Y, Hollmann TJ, Grisham RN, Erskine CL, Block MS, Knutson KL, O'Cearbhaill RE, Aghajanian C, Konner JA. Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial. J Immunother Cancer. 2020 Jun; 8 (1)
    View PubMed
  24. Manna A, Kellett T, Aulakh S, Lewis-Tuffin LJ, Dutta N, Knutson K, Chini E, Pinilla-Ibarz J, Lamanna N, Manochakian R, Malavasi F, Sher T, Chanan-Khan AA, Ailawadhi S, Paulus A. Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses. Blood Adv. 2020 May 26; 4 (10):2143-2157
    View PubMed
  25. Knutson KL, Block MS, Norton N, Erskine CL, Hobday TJ, Dietz AB, Padley D, Gustafson MP, Puglisi-Knutson D, Mangskau TK, Chumsri S, Dueck AC, Karyampudi L, Wilson G, Degnim AC. Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine. Clin Cancer Res. 2020 Mar 1; 26 (5):1045-1053 Epub 2019 Nov 22
    View PubMed
  26. Norton N, Youssef B, Hillman DW, Nassar A, Geiger XJ, Necela BM, Liu H, Ruddy KJ, Polley MC, Ingle JN, Couch FJ, Perez EA, Liu MC, Carter JM, Leon-Ferre RA, Boughey JC, Somers EB, Kalari KR, Visscher DW, Goetz MP, Knutson KL. Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. NPJ Breast Cancer. 2020 Feb 4; 6 (1):4 Epub 2020 Feb 04
    View PubMed
  27. Davis JM 3rd, Crowson CS, Knutson KL, Achenbach SJ, Strausbauch MA, Therneau TM, Matteson EL, Gabriel SE, Wettstein PJ. Longitudinal relationships between rheumatoid factor and cytokine expression by immunostimulated peripheral blood lymphocytes from patients with rheumatoid arthritis: New insights into B-cell activation. Clin Immunol. 2020 Feb; 211:108342 Epub 2020 Jan 08
    View PubMed
  28. Adhikary S, Hoskin TL, Stallings-Mann ML, Arshad M, Frost MH, Winham SJ, Pena A, Lee DJ, Murphy LM, Rakoff M, Denison LA, Knutson KL, Radisky DC, Visscher DW, Degnim AC. Cytotoxic T cell depletion with increasing epithelial abnormality in women with benign breast disease. Breast Cancer Res Treat. 2020 Feb; 180 (1):55-61 Epub 2020 Jan 13
    View PubMed
  29. Ren Y, Cherukuri Y, Wickland DP, Sarangi V, Tian S, Carter JM, Mansfield AS, Block MS, Sherman ME, Knutson KL, Lin Y, Asmann YW. HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer. Oncoimmunology. 2020; 9 (1):1744947 Epub 2020 Apr 01
    View PubMed
  30. Norton N, Youssef B, Hillman DW, Nassar A, Geiger XJ, Necela BM, Liu H, Ruddy KJ, Polley MC, Ingle JN, Couch FJ, Perez EA, Liu MC, Carter JM, Leon-Ferre RA, Boughey JC, Somers EB, Kalari KR, Visscher DW, Goetz MP, Knutson KL. Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. NPJ Breast Cancer. 2020; 6:4 Epub 2020 Feb 04
    View PubMed
  31. Chumsri S, Serie DJ, Li Z, Pogue-Geile KL, Soyano-Muller AE, Mashadi-Hossein A, Warren S, Lou Y, Colon-Otero G, Knutson KL, Perez EA, Moreno-Aspitia A, Thompson EA. Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials. Clin Cancer Res. 2019 Jul 15; 25 (14):4422-4430 Epub 2019 Feb 26
    View PubMed
  32. Lou Y, Marin-Acevedo JA, Vishnu P, Manochakian R, Dholaria B, Soyano A, Luo Y, Zhang Y, Knutson KL. Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy. Immunotherapy. 2019 May; 11 (7):577-584
    View PubMed
  33. Cannon MJ, Block MS, Morehead LC, Knutson KL. The evolving clinical landscape for dendritic cell vaccines and cancer immunotherapy. Immunotherapy. 2019 Feb; 11 (2):75-79
    View PubMed
  34. Soyano AE, Dholaria B, Marin-Acevedo JA, Diehl N, Hodge D, Luo Y, Manochakian R, Chumsri S, Adjei A, Knutson KL, Lou Y. Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. J Immunother Cancer. 2018 Nov 23; 6 (1):129
    View PubMed
  35. Qiu Y, Li Z, Pouzoulet F, Vishnu P, Copland JA 3rd, Knutson KL, Soussain C, Tun HW. Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model. Br J Haematol 2018 Nov; 183 (4):674-678 Epub 2017 Oct 26
    View PubMed
  36. Kalli KR, Block MS, Kasi PM, Erskine CL, Hobday TJ, Dietz A, Padley D, Gustafson MP, Shreeder B, Puglisi-Knutson D, Visscher DW, Mangskau TK, Wilson G, Knutson KL. Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res. 2018 Jul 1; 24 (13):3014-3025 Epub 2018 Mar 15
    View PubMed
  37. Norton N, Fox N, McCarl CA, Tenner KS, Ballman K, Erskine CL, Necela BM, Northfelt D, Tan WW, Calfa C, Pegram M, Colon-Otero G, Perez EA, Clynes R, Knutson KL. Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer. Breast Cancer Res. 2018 Jun 14; 20 (1):52 Epub 2018 June 14
    View PubMed
  38. Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018 Mar 15; 11 (1):39
    View PubMed
  39. Carter JM, Hoskin TL, Pena MA, Brahmbhatt R, Winham SJ, Frost MH, Stallings-Mann M, Radisky DC, Knutson KL, Visscher DW, Degnim AC. Macrophagic "Crown-like Structures" Are Associated with an Increased Risk of Breast Cancer in Benign Breast Disease. Cancer Prev Res (Phila). 2018 Feb; 11 (2):113-119 Epub 2017 Nov 22
    View PubMed
  40. Kerekes D, Visscher DW, Hoskin TL, Radisky DC, Brahmbhatt RD, Pena A, Frost MH, Arshad M, Stallings-Mann M, Winham SJ, Murphy L, Denison L, Carter JM, Knutson KL, Degnim AC. CD56+ immune cell infiltration and MICA are decreased in breast lobules with fibrocystic changes. Breast Cancer Res Treat. 2018 Feb; 167 (3):649-658 Epub 2017 Nov 01
    View PubMed
  41. Marin-Acevedo JA, Soyano AE, Dholaria B, Knutson KL, Lou Y. Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol. 2018 Jan 12; 11 (1):8
    View PubMed
  42. Lamichhane P, Karyampudi L, Shreeder B, Krempski J, Bahr D, Daum J, Kalli KR, Goode EL, Block MS, Cannon MJ, Knutson KL. IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer. Cancer Res. 2017 Dec 01; 77(23):6667-6678. Epub 2017 Oct 09.
    View PubMed
  43. Strege PR, Knutson K, Eggers SJ, Li JH, Wang F, Linden D, Szurszewski JH, Milescu L, Leiter AB, Farrugia G, Beyder A. Sodium channel NaV1.3 is important for enterochromaffin cell excitability and serotonin release. Sci Rep. 2017 Nov 15; 7 (1):15650
    View PubMed
  44. Yuan H, Jiang W, von Roemeling CA, Qie Y, Liu X, Chen Y, Wang Y, Wharen RE, Yun K, Bu G, Knutson KL, Kim BYS. Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. Nat Nanotechnol. 2017 Aug; 12 (8):763-769 Epub 2017 May 01
    View PubMed
  45. Degnim AC, Hoskin TL, Arshad M, Frost MH, Winham SJ, Brahmbhatt RA, Pena A, Carter JM, Stallings-Mann ML, Murphy LM, Miller EE, Denison LA, Vachon CM, Knutson KL, Radisky DC, Visscher DW. Alterations in the Immune Cell Composition in Premalignant Breast Tissue that Precede Breast Cancer Development. Clin Cancer Res. 2017 Jul 15; 23 (14):3945-3952 Epub 2017 Jan 26
    View PubMed
  46. Singh JA, Noorbaloochi S, Knutson KL. Cytokine and neuropeptide levels are associated with pain relief in patients with chronically painful total knee arthroplasty: a pilot study. BMC Musculoskelet Disord. 2017 Jan 14; 18 (1):17
    View PubMed
  47. Cannioto RA, Sucheston-Campbell LE, Hampras S, Goode EL, Knutson K, Ness R, Modugno F, Wallace P, Szender JB, Mayor P, Hong CC, Joseph JM, Friel G, Davis W, Nesline M, Eng KH, Edwards RP, Kruszka B, Schmitt K, Odunsi K, Moysich KB. The Association of Peripheral Blood Regulatory T-Cell Concentrations With Epithelial Ovarian Cancer: A Brief Report. Int J Gynecol Cancer. 2017 Jan; 27 (1):11-16
    View PubMed
  48. Wang F, Knutson K, Alcaino C, Linden DR, Gibbons SJ, Kashyap P, Grover M, Oeckler R, Gottlieb PA, Li HJ, Leiter AB, Farrugia G, Beyder A. Mechanosensitive ion channel Piezo2 is important for enterochromaffin cell response to mechanical forces. J Physiol. 2017 Jan 1; 595 (1):79-91 Epub 2016 Aug 13
    View PubMed
  49. Henle AM, Nassar A, Puglisi-Knutson D, Youssef B, Knutson KL. Downregulation of TAP1 and TAP2 in early stage breast cancer. PLoS One. 2017; 12 (11):e0187323 Epub 2017 Nov 01
    View PubMed
  50. Hampras SS, Sucheston-Campbell LE, Cannioto R, Chang-Claude J, Modugno F, Dork T, Hillemanns P, Preus L, Knutson KL, Wallace PK, Hong CC, Friel G, Davis W, Nesline M, Pearce CL, Kelemen LE, Goodman MT, Bandera EV, Terry KL, Schoof N, Eng KH, Clay A, Singh PK, Joseph JM, Aben KK, Anton-Culver H, Antonenkova N, Baker H, Bean Y, Beckmann MW, Bisogna M, Bjorge L, Bogdanova N, Brinton LA, Brooks-Wilson A, Bruinsma F, Butzow R, Campbell IG, Carty K, Cook LS, Cramer DW, Cybulski C, Dansonka-Mieszkowska A, Dennis J, Despierre E, Dicks E, Doherty JA, du Bois A, Durst M, Easton D, Eccles D, Edwards RP, Ekici AB, Fasching PA, Fridley BL, Gao YT, Gentry-Maharaj A, Giles GG, Glasspool R, Gronwald J, Harrington P, Harter P, Hasmad HN, Hein A, Heitz F, Hildebrandt MA, Hogdall C, Hogdall E, Hosono S, Iversen ES, Jakubowska A, Jensen A, Ji BT, Karlan BY, Kellar M, Kelley JL, Kiemeney LA, Klapdor R, Kolomeyevskaya N, Krakstad C, Kjaer SK, Kruszka B, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le ND, Lee AW, Lele S, Leminen A, Lester J, Levine DA, Liang D, Lissowska J, Liu S, Lu K, Lubinski J, Lundvall L, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, McNeish I, Menon U, Moes-Sosnowska J, Narod SA, Nedergaard L, Nevanlinna H, Nickels S, Olson SH, Orlow I, Weber RP, Paul J, Pejovic T, Pelttari LM, Perkins B, Permuth-Wey J, Pike MC, Plisiecka-Halasa J, Poole EM, Risch HA, Rossing MA, Rothstein JH, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schernhammer E, Schmitt K, Schwaab I, Shu XO, Shvetsov YB, Siddiqui N, Sieh W, Song H, Southey MC, Tangen IL, Teo SH, Thompson PJ, Timorek A, Tsai YY, Tworoger SS, Tyrer J, van Altena AM, Vergote I, Vierkant RA, Walsh C, Wang-Gohrke S, Wentzensen N, Whittemore AS, Wicklund KG, Wilkens LR, Wu AH, Wu X, Woo YL, Yang H, Zheng W, Ziogas A, Gayther SA, Ramus SJ, Sellers TA, Schildkraut JM, Phelan CM, Berchuck A, Chenevix-Trench G, Cunningham JM, Pharoah PP, Ness RB, Odunsi K, Goode EL, Moysich KB. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget. 2016 Oct 25; 7 (43):69097-69110
    View PubMed
  51. Knutson KL, Karyampudi L, Lamichhane P, Preston C. Retraction Note: Targeted immune therapy of ovarian cancer. Cancer Metastasis Rev. 2016 Sep; 35 (3):489
    View PubMed
  52. Hieken TJ, Chen J, Hoskin TL, Walther-Antonio M, Johnson S, Ramaker S, Xiao J, Radisky DC, Knutson KL, Kalari KR, Yao JZ, Baddour LM, Chia N, Degnim AC. The Microbiome of Aseptically Collected Human Breast Tissue in Benign and Malignant Disease. Sci Rep. 2016 Aug 3; 6:30751 Epub 2016 Aug 03
    View PubMed
  53. Knutson KL, Clynes R, Shreeder B, Yeramian P, Kemp KP, Ballman K, Tenner KS, Erskine CL, Norton N, Northfelt D, Tan W, Calfa C, Pegram M, Mittendorf EA, Perez EA. Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain. Cancer Res. 2016 Jul 1; 76 (13):3702-10 Epub 2016 Apr 20
    View PubMed
  54. Karyampudi L, Lamichhane P, Krempski J, Kalli KR, Behrens MD, Vargas DM, Hartmann LC, Janco JM, Dong H, Hedin KE, Dietz AB, Goode EL, Knutson KL. PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-kappaB. Cancer Res. 2016 Jan 15; 76 (2):239-50 Epub 2015 Nov 13
    View PubMed
  55. Knutson KL, Maurer MJ, Preston CC, Moysich KB, Goergen K, Hawthorne KM, Cunningham JM, Odunsi K, Hartmann LC, Kalli KR, Oberg AL, Goode EL. Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer. Cancer Immunol Immunother. 2015 Dec; 64 (12):1495-504 Epub 2015 Aug 23
    View PubMed
  56. Escalante P, Peikert T, Van Keulen VP, Erskine CL, Bornhorst CL, Andrist BR, Mccoy K, Pease LR, Abraham RS, Knutson KL, Kita H, Schrum AG, Limper AH. Combinatorial immunoprofiling in latent tuberculosis infection. Toward better risk stratification American Journal of Respiratory & Critical Care Medicine. 2015 Sep 1; 192: (5)605-17.
  57. Escalante P, Peikert T, Van Keulen VP, Erskine CL, Bornhorst CL, Andrist BR, McCoy K, Pease LR, Abraham RS, Knutson KL, Kita H, Schrum AG, Limper AH. Combinatorial Immunoprofiling in Latent Tuberculosis Infection. Toward Better Risk Stratification. Am J Respir Crit Care Med. 2015 Sep 1; 192 (5):605-17
    View PubMed
  58. Block MS, Maurer MJ, Goergen K, Kalli KR, Erskine CL, Behrens MD, Oberg AL, Knutson KL. Plasma immune analytes in patients with epithelial ovarian cancer. Cytokine. 2015 May; 73 (1):108-13 Epub 2015 Mar 03
    View PubMed
  59. Tran Janco JM, Lamichhane P, Karyampudi L, Knutson KL. Tumor-infiltrating dendritic cells in cancer pathogenesis. J Immunol. 2015 Apr 1; 194 (7):2985-91
    View PubMed
  60. Knutson KL, Karyampudi L, Lamichhane P, Preston C. Targeted immune therapy of ovarian cancer. Cancer Metastasis Rev. 2015 Mar; 34 (1):53-74
    View PubMed
  61. Galanis E, Atherton PJ, Maurer MJ, Knutson KL, Dowdy SC, Cliby WA, Haluska P Jr, Long HJ, Oberg A, Aderca I, Block MS, Bakkum-Gamez J, Federspiel MJ, Russell SJ, Kalli KR, Keeney G, Peng KW, Hartmann LC. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res. 2015 Jan 1; 75 (1):22-30 Epub 2014 Nov 14
    View PubMed
  62. Norton N, Olson RM, Pegram M, Tenner K, Ballman KV, Clynes R, Knutson KL, Perez EA. Association studies of Fcgamma receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831. Cancer Immunol Res. 2014 Oct; 2 (10):962-9 Epub 2014 July 02
    View PubMed
  63. Block MS, Charbonneau B, Vierkant RA, Fogarty Z, Bamlet WR, Pharoah PD, Rossing MA, Cramer D, Pearce CL, Schildkraut J, Menon U, Kjaer SK, Levine DA, Gronwald J, Culver HA, Whittemore AS, Karlan BY, Lambrechts D, Wentzensen N, Kupryjanczyk J, Chang-Claude J, Bandera EV, Hogdall E, Heitz F, Kaye SB, Fasching PA, Campbell I, Goodman MT, Pejovic T, Bean YT, Hays LE, Lurie G, Eccles D, Hein A, Beckmann MW, Ekici AB, Paul J, Brown R, Flanagan JM, Harter P, du Bois A, Schwaab I, Hogdall CK, Lundvall L, Olson SH, Orlow I, Paddock LE, Rudolph A, Eilber U, Dansonka-Mieszkowska A, Rzepecka IK, Ziolkowska-Seta I, Brinton LA, Yang H, Garcia-Closas M, Despierre E, Lambrechts S, Vergote I, Walsh CS, Lester J, Sieh W, McGuire V, Rothstein JH, Ziogas A, Lubinski J, Cybulski C, Menkiszak J, Jensen A, Gayther SA, Ramus SJ, Gentry-Maharaj A, Berchuck A, Wu AH, Pike MC, Van Den Berg D, Terry KL, Vitonis AF, Ramirez SM, Rider DN, Knutson KL, Sellers TA, Phelan CM, Doherty JA, Johnatty SE, deFazio A, Song H, Tyrer J, Kalli KR, Fridley BL, Cunningham JM, Goode EL, Georgia Chenevix-Trench//for AOCS///ACS Group. Variation in NF-kappaB signaling pathways and survival in invasive epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2014 Jul; 23 (7):1421-7 Epub 2014 Apr 16
    View PubMed
  64. Karyampudi L, Lamichhane P, Scheid AD, Kalli KR, Shreeder B, Krempski JW, Behrens MD, Knutson KL. Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Res. 2014 Jun 1; 74 (11):2974-85 Epub 2014 Apr 11
    View PubMed
  65. Wang C, Cicek MS, Charbonneau B, Kalli KR, Armasu SM, Larson MC, Konecny GE, Winterhoff B, Fan JB, Bibikova M, Chien J, Shridhar V, Block MS, Hartmann LC, Visscher DW, Cunningham JM, Knutson KL, Fridley BL, Goode EL. Tumor hypomethylation at 6p21.3 associates with longer time to recurrence of high-grade serous epithelial ovarian cancer. Cancer Res. 2014 Jun 1; 74 (11):3084-91 Epub 2014 Apr 11
    View PubMed
  66. Charbonneau B, Moysich KB, Kalli KR, Oberg AL, Vierkant RA, Fogarty ZC, Block MS, Maurer MJ, Goergen KM, Fridley BL, Cunningham JM, Rider DN, Preston C, Hartmann LC, Lawrenson K, Wang C, Tyrer J, Song H, deFazio A, Johnatty SE, Doherty JA, Phelan CM, Sellers TA, Ramirez SM, Vitonis AF, Terry KL, Van Den Berg D, Pike MC, Wu AH, Berchuck A, Gentry-Maharaj A, Ramus SJ, Diergaarde B, Shen H, Jensen A, Menkiszak J, Cybulski C, Lubilski J, Ziogas A, Rothstein JH, McGuire V, Sieh W, Lester J, Walsh C, Vergote I, Lambrechts S, Despierre E, Garcia-Closas M, Yang H, Brinton LA, Spiewankiewicz B, Rzepecka IK, Dansonka-Mieszkowska A, Seibold P, Rudolph A, Paddock LE, Orlow I, Lundvall L, Olson SH, Hogdall CK, Schwaab I, du Bois A, Harter P, Flanagan JM, Brown R, Paul J, Ekici AB, Beckmann MW, Hein A, Eccles D, Lurie G, Hays LE, Bean YT, Pejovic T, Goodman MT, Campbell I, Fasching PA, Konecny G, Kaye SB, Heitz F, Hogdall E, Bandera EV, Chang-Claude J, Kupryjanczyk J, Wentzensen N, Lambrechts D, Karlan BY, Whittemore AS, Culver HA, Gronwald J, Levine DA, Kjaer SK, Menon U, Schildkraut JM, Pearce CL, Cramer DW, Rossing MA, Chenevix-Trench G, AOCS group, Acs, Pharoah PD, Gayther SA, Ness RB, Odunsi K, Sucheston LE, Knutson KL, Goode EL. Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. Cancer Immunol Res. 2014 Apr; 2(4):332-40. Epub 2014 Jan 27.
    View PubMed
  67. Degnim AC, Brahmbhatt RD, Radisky DC, Hoskin TL, Stallings-Mann M, Laudenschlager M, Mansfield A, Frost MH, Murphy L, Knutson K, Visscher DW. Immune cell quantitation in normal breast tissue lobules with and without lobulitis. Breast Cancer Res Treat. 2014 Apr; 144 (3):539-49 Epub 2014 Mar 05
    View PubMed
  68. Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Knutson KL. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene. 2014 Mar 6; 33 (10):1316-24 Epub 2013 Mar 11
    View PubMed
  69. Charbonneau B, Block MS, Bamlet WR, Vierkant RA, Kalli KR, Fogarty Z, Rider DN, Sellers TA, Tworoger SS, Poole E, Risch HA, Salvesen HB, Kiemeney LA, Baglietto L, Giles GG, Severi G, Trabert B, Wentzensen N, Chenevix-Trench G, Whittemore AS, Sieh W, Chang-Claude J, Bandera EV, Orlow I, Terry K, Goodman MT, Thompson PJ, Cook LS, Rossing MA, Ness RB, Narod SA, Kupryjanczyk J, Lu K, Butzow R, Dork T, Pejovic T, Campbell I, Le ND, Bunker CH, Bogdanova N, Runnebaum IB, Eccles D, Paul J, Wu AH, Gayther SA, Hogdall E, Heitz F, Kaye SB, Karlan BY, Anton-Culver H, Gronwald J, Hogdall CK, Lambrechts D, Fasching PA, Menon U, Schildkraut J, Pearce CL, Levine DA, Kjaer SK, Cramer D, Flanagan JM, Phelan CM, Brown R, Massuger LF, Song H, Doherty JA, Krakstad C, Liang D, Odunsi K, Berchuck A, Jensen A, Lubinski J, Nevanlinna H, Bean YT, Lurie G, Ziogas A, Walsh C, Despierre E, Brinton L, Hein A, Rudolph A, Dansonka-Mieszkowska A, Olson SH, Harter P, Tyrer J, Vitonis AF, Brooks-Wilson A, Aben KK, Pike MC, Ramus SJ, Wik E, Cybulski C, Lin J, Sucheston L, Edwards R, McGuire V, Lester J, Edwards R, du Bois A, Lundvall L, Wang-Gohrke S, Szafron LM, Lambrechts S, Yang H, Beckmann MW, Pelttari LM, Van Altena AM, van den Berg D, Halle MK, Gentry-Maharaj A, Schwaab I, Chandran U, Menkiszak J, Ekici AB, Wilkens LR, Leminen A, Modugno F, Friel G, Rothstein JH, Vergote I, Garcia-Closas M, Hildebrandt MA, Sobiczewski P, Kelemen LE, Pharoah PD, Moysich K, Knutson KL, Cunningham JM, Fridley BL, Goode EL, for AOCS/ACS group. Risk of ovarian cancer and the NF-kappaB pathway: genetic association with IL1A and TNFSF10. Cancer Res. 2014 Feb 1; 74 (3):852-61 Epub 2013 Nov 22
    View PubMed
  70. Crowson CS, Liao KP, Davis JM 3rd, Solomon DH, Matteson EL, Knutson KL, Hlatky MA, Gabriel SE. Rheumatoid arthritis and cardiovascular disease. Am Heart J. 2013 Oct; 166 (4):622-628.e1 Epub 2013 Aug 29
    View PubMed
  71. Carlson AM, Maurer MJ, Goergen KM, Kalli KR, Erskine CL, Behrens MD, Knutson KL, Block MS. Utility of progranulin and serum leukocyte protease inhibitor as diagnostic and prognostic biomarkers in ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2013 Oct; 22 (10):1730-5 Epub 2013 July 22
    View PubMed
  72. Derycke MS, Charbonneau B, Preston CC, Kalli KR, Knutson KL, Rider DN, Goode EL. Toward understanding the genetics of regulatory T cells in ovarian cancer. Oncoimmunology. 2013 Jun 1; 2 (6):e24535 Epub 2013 Apr 16
    View PubMed
  73. Pavelko KD, Bell MP, Karyampudi L, Hansen MJ, Allen KS, Knutson KL, Pease LR. The epitope integration site for vaccine antigens determines virus control while maintaining efficacy in an engineered cancer vaccine. Mol Ther. 2013 May; 21 (5):1087-95 Epub 2013 Apr 09
    View PubMed
  74. Mader EK, Butler G, Dowdy SC, Mariani A, Knutson KL, Federspiel MJ, Russell SJ, Galanis E, Dietz AB, Peng KW. Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med. 2013 Jan 24; 11:20
    View PubMed
  75. Charbonneau B, Goode EL, Kalli KR, Knutson KL, Derycke MS. The immune system in the pathogenesis of ovarian cancer. Crit Rev Immunol. 2013; 33 (2):137-64
    View PubMed
  76. Henle AM, Erskine CL, Benson LM, Clynes R, Knutson KL. Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cells. J Immunol. 2013 Jan 1; 190 (1):479-88 Epub 2012 Nov 23
    View PubMed
  77. Goode EL, DeRycke M, Kalli KR, Oberg AL, Cunningham JM, Maurer MJ, Fridley BL, Armasu SM, Serie DJ, Ramar P, Goergen K, Vierkant RA, Rider DN, Sicotte H, Wang C, Winterhoff B, Phelan CM, Schildkraut JM, Weber RP, Iversen E, Berchuck A, Sutphen R, Birrer MJ, Hampras S, Preus L, Gayther SA, Ramus SJ, Wentzensen N, Yang HP, Garcia-Closas M, Song H, Tyrer J, Pharoah PP, Konecny G, Sellers TA, Ness RB, Sucheston LE, Odunsi K, Hartmann LC, Moysich KB, Knutson KL. Inherited variants in regulatory T cell genes and outcome of ovarian cancer. PLoS One. 2013; 8 (1):e53903 Epub 2013 Jan 30
    View PubMed
  78. Davis JM, Knutson KL, Strausbauch MA, Green AB, Crowson CS, Therneau TM, Matteson EL, Gabriel SE. Immune response profiling in early rheumatoid arthritis: discovery of a novel interaction of treatment response with viral immunity. Arthritis Res Ther. 2013; 15(6):R199.
    View PubMed
  79. Preston CC, Maurer MJ, Oberg AL, Visscher DW, Kalli KR, Hartmann LC, Goode EL, Knutson KL. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS One. 2013; 8 (11):e80063 Epub 2013 Nov 14
    View PubMed
  80. Erskine CL, Henle AM, Knutson KL. Determining optimal cytotoxic activity of human Her2neu specific CD8 T cells by comparing the Cr51 release assay to the xCELLigence system. J Vis Exp. 2012 Aug 8; (66):e3683 Epub 2012 Aug 08
    View PubMed
  81. Davis JM 3rd, Knutson KL, Skinner JA, Strausbauch MA, Crowson CS, Therneau TM, Wettstein PJ, Matteson EL, Gabriel SE. A profile of immune response to herpesvirus is associated with radiographic joint damage in rheumatoid arthritis. Arthritis Res Ther. 2012 Jan 31; 14 (1):R24
    View PubMed
  82. Juskewitch JE, Platt JL, Knudsen BE, Knutson KL, Brunn GJ, Grande JP. Disparate roles of marrow- and parenchymal cell-derived TLR4 signaling in murine LPS-induced systemic inflammation. Sci Rep. 2012; 2:918 Epub 2012 Dec 04
    View PubMed
  83. Juskewitch JE, Knudsen BE, Platt JL, Nath KA, Knutson KL, Brunn GJ, Grande JP. LPS-induced murine systemic inflammation is driven by parenchymal cell activation and exclusively predicted by early MCP-1 plasma levels. Am J Pathol. 2012 Jan; 180 (1):32-40 Epub 2011 Nov 07
    View PubMed
  84. Shire AM, Sandhu DS, Kaiya JK, Oseini AM, Yang JD, Chaiteerakij R, Mettler TA, Giama NH, Roberts RO, Therneau TM, Petersen GM, Knutson KL, Roberts LR. Viral hepatitis among Somali immigrants in Minnesota: association of hepatitis C with hepatocellular carcinoma. Mayo Clin Proc. 2012 Jan; 87 (1):17-24
    View PubMed
  85. Krause ML, Davis JM 3rd, Knutson KL, Strausbauch MA, Crowson CS, Therneau TM, Wettstein PJ, Matteson EL, Gabriel SE. Assessing immune function by profiling cytokine release from stimulated blood leukocytes and the risk of infection in rheumatoid arthritis. Clin Immunol. 2011 Oct; 141 (1):67-72 Epub 2011 May 30
    View PubMed
  86. Erskine CL, Krco CJ, Hedin KE, Borson ND, Kalli KR, Behrens MD, Heman-Ackah SM, von Hofe E, Wettstein PJ, Mohamadzadeh M, Knutson KL. MHC class II epitope nesting modulates dendritic cell function and improves generation of antigen-specific CD4 helper T cells. J Immunol. 2011 Jul 1; 187 (1):316-24 Epub 2011 May 25
    View PubMed
  87. Asiedu MK, Ingle JN, Behrens MD, Radisky DC, Knutson KL. TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res. 2011 Jul 1; 71 (13):4707-19 Epub 2011 May 09
    View PubMed
  88. Krempski J, Karyampudi L, Behrens MD, Erskine CL, Hartmann L, Dong H, Goode EL, Kalli KR, Knutson KL. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol. 2011 Jun 15; 186 (12):6905-13 Epub 2011 May 06
    View PubMed
  89. Davis JM 3rd, Knutson KL, Strausbauch MA, Crowson CS, Therneau TM, Wettstein PJ, Roger VL, Matteson EL, Gabriel SE. A signature of aberrant immune responsiveness identifies myocardial dysfunction in rheumatoid arthritis. Arthritis Rheum. 2011 Jun; 63 (6):1497-506
    View PubMed
  90. White KL, Rider DN, Kalli KR, Knutson KL, Jarvik GP, Goode EL. Genomics of the NF-kappaB signaling pathway: hypothesized role in ovarian cancer. Cancer Causes Control. 2011 May; 22 (5):785-801 Epub 2011 Feb 27
    View PubMed
  91. Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson KL. Immunity and immune suppression in human ovarian cancer. Immunotherapy. 2011 Apr; 3 (4):539-56
    View PubMed
  92. Krause ML, Davis JM, Knutson KL, Strausbauch MA, Crowson CS, Therneau TM, Wettstein PJ, Matteson EL, Gabriel SE. Corrigendum to "Assessing immune function by profiling cytokine release from stimulated blood leukocytes and the risk of infection in rheumatoid arthritis" [Clin. Immunol. 141 (2011) 67-72]. Clin Immunol. 2011; 141(3):372.
  93. Morales JK, Kmieciak M, Knutson KL, Bear HD, Manjili MH. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat. 2010 Aug; 123(1):39-49. Epub 2009 Nov 08.
    View PubMed
  94. Davis JM 3rd, Knutson KL, Strausbauch MA, Crowson CS, Therneau TM, Wettstein PJ, Matteson EL, Gabriel SE. Analysis of complex biomarkers for human immune-mediated disorders based on cytokine responsiveness of peripheral blood cells. J Immunol. 2010 Jun 15; 184 (12):7297-304 Epub 2010 May 21
    View PubMed
  95. Norell H, Poschke I, Charo J, Wei WZ, Erskine C, Piechocki MP, Knutson KL, Bergh J, Lidbrink E, Kiessling R. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J. transl. med. 2010 Jun 7; 8.
  96. Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother. 2010 Jun; 59(6):943-53. Epub 2010 Feb 06.
    View PubMed
  97. Taylor JA, Cummins NW, Bren GD, Rizza SA, Kolbert CP, Behrens MD, Knutson KL, Kahl JC, Asmann YW, Badley AD. Casp8p41 expression in primary T cells induces a proinflammatory response. AIDS. 2010 Jun 1; 24(9):1251-8.
    View PubMed
  98. Radhakrishnan S, Wiehagen KR, Pulko V, Van Keulen V, Faubion WA, Knutson KL, Pease LR. Induction of a Th1 response from Th2-polarized T cells by activated dendritic cells: dependence on TCR: peptide-MHC interaction, ICAM-1, IL-12, and IFN-gamma (Retraction 178, pg 3583, 2007) Journal Of Immunology. 2010 Jun 1; 184 (11):6555
  99. Reiman JM, Knutson KL, Radisky DC. Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells. Cancer Res. 2010 Apr 15; 70 (8):3005-8
    View PubMed
  100. Karyampudi L, Formicola C, Erskine CL, Maurer MJ, Ingle JN, Krco CJ, Wettstein PJ, Kalli KR, Fikes JD, Beebe M, Hartmann LC, Disis ML, Ferrone S, Ishioka G, Knutson KL. A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102. Clin Cancer Res. 2010 Feb 1; 16 (3):825-34 Epub 2010 Jan 26
    View PubMed
  101. Karyampudi L, Knutson KL. Antibodies in cancer immunotherapy. Cancer Biomark. 2010; 6 (5-6):291-305
    View PubMed
  102. Karyampudi L, Krco CJ, Kalli KR, Erskine CL, Hartmann LC, Goodman K, Ingle JN, Maurer MJ, Nassar A, Yu C, Disis ML, Wettstein PJ, Fikes JD, Beebe M, Ishioka G, Knutson KL. Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen. Cancer Immunol Immunother. 2010 Jan; 59 (1):161-71 Epub 2009 July 21
    View PubMed
  103. Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology. 2009 Oct; 137 (4):1270-9 Epub 2009 July 03
    View PubMed
  104. Basal E, Eghbali-Fatourechi GZ, Kalli KR, Hartmann LC, Goodman KM, Goode EL, Kamen BA, Low PS, Knutson KL. Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. PLoS One. 2009 Jul 20; 4 (7):e6292 Epub 2009 July 20
    View PubMed
  105. White KL, Vierkant RA, Phelan CM, Fridley BL, Anderson S, Knutson KL, Schildkraut JM, Cunningham JM, Kelemen LE, Pankratz VS, Rider DN, Liebow M, Hartmann LC, Sellers TA, Goode EL. Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer. BMC Cancer. 2009 Jun 06; 9:170.
    View PubMed
  106. Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC, Manjili MH, Radisky DC, Ferrone S, Knutson KL. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res. 2009 Apr 1; 69 (7):2887-95 Epub 2009 Mar 10
    View PubMed
  107. Gustafson MP, Knutson KL, Dietz AB. Therapeutic vaccines for malignant brain tumors. Biologics. 2008 Dec; 2(4):753-61.
    View PubMed
  108. Shepard BD, De Forni D, McNamara DR, Foli A, Rizza SA, Abraham RS, Knutson K, Wettstein PJ, Lori F, Badley AD. Beneficial effect of TRAIL on HIV burden, without detectable immune consequences. PLoS One. 2008 Aug 28; 3 (8):e3096
    View PubMed
  109. Kalli KR, Krco CJ, Hartmann LC, Goodman K, Maurer MJ, Yu C, Johnson EM, Erskine CL, Disis ML, Wettstein PJ, Fikes JD, Beebe M, Ishioka G, Knutson KL. An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer. Cancer Res. 2008 Jun 15; 68 (12):4893-901
    View PubMed
  110. Worschech A, Kmieciak M, Knutson KL, Bear HD, Szalay AA, Wang E, Marincola FM, Manjili MH. Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Res. 2008 Apr 1; 68(7):2436-46.
    View PubMed
  111. Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, Hartmann LC. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008 Mar; 108 (3):619-26 Epub 2008 Jan 28
    View PubMed
  112. Behrens MD, Wagner WM, Krco CJ, Erskine CL, Kalli KR, Krempski J, Gad EA, Disis ML, Knutson KL. The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood. 2008 Feb 1; 111 (3):1472-9 Epub 2007 Nov 20
    View PubMed
  113. Tracz MJ, Juncos JP, Croatt AJ, Ackerman AW, Grande JP, Knutson KL, Kane GC, Terzic A, Griffin MD, Nath KA. Deficiency of heme oxygenase-1 impairs renal hemodynamics and exaggerates systemic inflammatory responses to renal ischemia. Kidney Int. 2007 Nov; 72 (9):1073-80 Epub 2007 Aug 29
    View PubMed
  114. Taylor C, Hershman D, Shah N, Suciu-Foca N, Petrylak DP, Taub R, Vahdat L, Cheng B, Pegram M, Knutson KL, Clynes R. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res. 2007 Sep 1; 13(17):5133-43.
    View PubMed
  115. Reiman JM, Kmieciak M, Manjili MH, Knutson KL. Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol. 2007 Aug; 17 (4):275-87 Epub 2007 June 26
    View PubMed
  116. Tracz MJ, Juncos JP, Grande JP, Croatt AJ, Ackerman AW, Rajagopalan G, Knutson KL, Badley AD, Griffin MD, Alam J, Nath KA. Renal hemodynamic, inflammatory, and apoptotic responses to lipopolysaccharide in HO-1-/- mice. Am J Pathol. 2007 Jun; 170 (6):1820-30
    View PubMed
  117. Siddiqui SA, Frigola X, Bonne-Annee S, Mercader M, Kuntz SM, Krambeck AE, Sengupta S, Dong H, Cheville JC, Lohse CM, Krco CJ, Webster WS, Leibovich BC, Blute ML, Knutson KL, Kwon ED. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res. 2007 Apr 1; 13 (7):2075-81
    View PubMed
  118. Radhakrishnan S, Wiehagen KR, Pulko V, Van Keulen V, Faubion WA, Van Keulen VP, Knutson KL, Pease LR. Induction of a Th1 response from Th2-polarized T cells by activated dendritic cells: Dependence on TCR : peptide-MHC interaction, ICAM-1, IL-12, and IFN-gamma. [RETRACTED PUBLICATION] Journal of Immunology. 2007 Mar 15; 178 (6):3583-92
    View PubMed
  119. Kmieciak M, Knutson KL, Dumur CI, Manjili MH. HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur J Immunol. 2007 Mar; 37(3):675-85.
    View PubMed
  120. Knutson KL, Disis ML, Salazar LG. CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother. 2007 Mar; 56 (3):271-85 Epub 2006 July 04
    View PubMed
  121. Nava-Parada P, Forni G, Knutson KL, Pease LR, Celis E. Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res. 2007 Feb 1; 67 (3):1326-34
    View PubMed
  122. Knutson KL, Krco CJ, Erskine CL, Goodman K, Kelemen LE, Wettstein PJ, Low PS, Hartmann LC, Kalli KR. T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. J Clin Oncol. 2006 Sep 10; 24(26):4254-61. Epub 2006 Aug 14.
    View PubMed
  123. Knutson KL, Lu H, Stone B, Reiman JM, Behrens MD, Prosperi CM, Gad EA, Smorlesi A, Disis ML. Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol. 2006 Aug 1; 177 (3):1526-33
    View PubMed
  124. Knutson KL, Dang Y, Lu H, Lukas J, Almand B, Gad E, Azeke E, Disis ML. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol. 2006 Jul 1; 177 (1):84-91
    View PubMed
  125. Knutson KL. Strong-arming immune regulation: suppressing regulatory T-cell function to treat cancers. Future Oncol. 2006 Jun; 2 (3):379-89
    View PubMed
  126. Knutson KL, dela Rosa C, Disis ML. Laboratory analysis of T-cell immunity. Front Biosci. 2006 May 1; 11:1932-44 Epub 2006 May 01
    View PubMed
  127. Manjili MH, Arnouk H, Knutson KL, Kmieciak M, Disis ML, Subjeck JR, Kazim AL. Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals". Breast Cancer Res Treat. 2006 Apr; 96(3):233-41. Epub 2005 Oct 07.
    View PubMed
  128. Lu H, Knutson KL, Gad E, Disis ML. The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens. Cancer Res. 2006; 66(19):9754-61.
  129. Knutson KL, Wagner W, Disis ML. Adoptive T cell therapy of solid cancers. Cancer Immunol Immunother. 2006 Jan; 55 (1):96-103 Epub 2005 Oct 27
    View PubMed
  130. Knutson KL, Disis ML. Augmenting T helper cell immunity in cancer. Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec; 5 (4):365-71
    View PubMed
  131. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother. 2005 Aug; 54 (8):721-8 Epub 2005 Jan 27
    View PubMed
  132. Knutson KL. Cancer vaccines: The next generation. Drug Discovery Today: Therapeutic Strategies. 2005; 2(4):323-30.
  133. Disis ML, Goodell V, Schiffman K, Knutson KL. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J Clin Immunol. 2004 Sep; 24(5):571-8.
    View PubMed
  134. Knutson KL, Almand B, Dang Y, Disis ML. Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res. 2004 Feb 1; 64(3):1146-51.
    View PubMed
  135. Salazar LG, Fikes J, Southwood S, Ishioka G, Knutson KL, Gooley TA, Schiffman K, Disis ML. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high affinity binding to multiple class II alleles. Clinical Cancer Research. 2004; 9:5559-55565.
  136. Knutson KL, Disis ML. IL-12 enhances the generation funciton tumor antigen-specific Th1 CD4 T cells during ex vivo expansion. Clin and Exp Immunol. 2004; 135:322-329.
  137. Disis ML, Schiffman K, Guthrie K, Salazar LG, Knutson KL, Goodell V, dela Rosa C, Cheever MA. Effect of dose on immune response in patients vaccinated with a HER-2/neu intracellular domain protein based vaccine. J Cin Oncol. 200425 2004; 22:1916-1925.
  138. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Immunology. 2004; 10:942-949.
  139. Curiel TJ, Wei S, Dong HD, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, David O, Burow M, Gordon A, Dhurandhar N, Myers L, Berggren R, Hemminki A, Alvarez RD, Emilie D, Curiel DT, Chen LP, Zou WP. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003 May; 9(5):562-7.
    View PubMed
  140. McNeel DG, Knutson KL, Schiffman K, Davis D, Caron D, Disis ML. Phase I study of an HLA-A2 peptide-based vaccine targeting HER-2/neu in patients with advanced stage prostate cancer. J Clinical Immunology. 2003; 23:62-72.
  141. Disis ML, Shiota FM, McNeel DG, Knutson KL. Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens. Immunobiology. 2003; 207(3):179-86.
    View PubMed
  142. Disis ML, Scholler N, Dahlin A, Pullman J, Knutson KL, Hellstrom KE, Hellstrom I. Plasmid-based vaccines encoding rat neu and co-stimulatory molecules elicit neu-specific immunity. Mol Ther Cancer. 2003; 2:995-1002.
  143. Knutson KL, Disis ML. Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient. Hum Immunol. 2002 Jul; 63(7):547-57.
    View PubMed
  144. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol. 2002 Jun 1; 20(11):2624-32.
    View PubMed
  145. Knutson KL, Schiffman K, Cheever MA, Disis ML. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res. 2002 May; 8(5):1014-8.
    View PubMed
  146. Disis ML, Rinn K, Knutson KL, Davis D, Caron D, dela Rosa C, Schiffman K. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood. 2002 Apr 15; 99(8):2845-50.
    View PubMed
  147. Knutson KL, Disis ML. Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine. Clin Breast Cancer. 2001 Apr; 2(1):73-9.
    View PubMed
  148. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest. 2001 Feb; 107(4):477-84.
    View PubMed
  149. Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat. 2000 Aug; 62(3):245-52.
    View PubMed
  150. Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin Cancer Res. 2000 Apr; 6(4):1347-50.
    View PubMed
  151. Hmama Z, Nandan D, Sly L, Knutson KL, Herrera-Velit P, Reiner NE. 1alpha,25-dihydroxyvitamin D(3)-induced myeloid cell differentiation is regulated by a vitamin D receptor-phosphatidylinositol 3-kinase signaling complex. J Exp Med. 1999 Dec 6; 190(11):1583-94.
    View PubMed
  152. Hmama Z, Knutson KL, Herrera-Velit P, Nandan D, Reiner NE. Monocyte adherence induced by lipopolysaccharide involves CD14, LFA-1, and cytohesin-1. Regulation by Rho and phosphatidylinositol 3-kinase. J Biol Chem. 1999 Jan 8; 274(2):1050-7.
    View PubMed
  153. Knutson KL, Hmama Z, Herrera-Velit P, Rochford R, Reiner NE. Lipoarabinomannan of Mycobacterium tuberculosis promotes protein tyrosine dephosphorylation and inhibition of mitogen-activated protein kinase in human mononuclear phagocytes. Role of the Src homology 2 containing tyrosine phosphatase 1. J Biol Chem. 1998 Jan 2; 273(1):645-52.
    View PubMed
  154. Herrera-Velit P, Knutson KL, Reiner NE. Phosphatidylinositol 3-kinase-dependent activation of protein kinase C-zeta in bacterial lipopolysaccharide-treated human monocytes. J Biol Chem. 1997 Jun 27; 272(26):16445-52.
    View PubMed
  155. Knutson KL, Hoenig M. Arachidonic acid-induced down-regulation of protein kinase C delta in beta-cells. J Cell Biochem. 1996 Sep 15; 62(4):543-52.
    View PubMed
  156. Knutson KL, Hoenig M. Regulation of distinct pools of protein kinase C delta in beta cells. J Cell Biochem. 1996 Jan; 60(1):130-8.
    View PubMed
  157. Knutson KL, Hoenig M. Identification and subcellular characterization of protein kinase-C isoforms in insulinoma beta-cells and whole islets. Endocrinology. 1994 Sep; 135(3):881-6.
    View PubMed
  158. Hoenig M, Knutson KL. Effect of protein kinase C on the plasma membrane calcium pump in purified beta cells. Biochemical Medicine and Metabolic Biology. 1994 1994; 53:75-79.
  159. Zalups RK, Knutson KL, Schnellmann RG. In vitro analysis of the accumulation and toxicity of inorganic mercury in segments of the proximal tubule isolated from the rabbit kidney. Toxicology and Applied Pharmacology 9. 1993; 119: 221-7.